ADRX-0706 is a Nectin-4 ADC being evaluated in the Phase 1b portion of an ongoing Phase 1a/b clinical trial (NCT06036121) for the treatment of select advanced solid tumors, including cervical cancer.

First clinical data from ADRX-0706 Phase 1a supports its differentiated safety, PK, and efficacy profile Adcentrx will deliver a poster presentation on ADRX-0706, a clinical-stage Nectin-4 ADC.